NASDAQ · OKYO
OKYO Pharma Limited
$1.48-$0.02 (-1.33%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.75% below the high.
Loading market information…
NASDAQ · ANGN · USD
Stock price, earnings
Quote as of Jun 1, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Angion Biomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 95.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Angion Biomedica Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 | Mar 30, 2022 | $0.58+193.55% vs estimate | $25.94M |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.48-$0.02 (-1.33%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.75% below the high.
$0.55$0.00 (0.0%)
Marinus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.76% below the high.
$2.02+$0.13 (+6.61%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.7% below the high.
$0.98$0.00 (0.0%)
American Hemp Ventures, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.82% below the high.
$1.35+$0.09 (+7.14%)
Channel Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 97.51% below the high.
$0.14$0.00 (0.0%)
Omega Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
$0.41$0.00 (0.0%)
CohBar, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.41% below the high.
$0.32-$0.17 (-34.28%)
InVivo Therapeutics Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 86.64% below the high.
